Searched for
MYLAN
Mylan launches remdesivir in India under the brand name DESREM for Covid-19 treatmentThe drug is approved for the treatment of suspected or laboratory confirmed incidences of Covid-19 in adults and children hospitalised with...- Mylan gets DCGI nod for remdesivir in India, to launch at Rs 4,800 per vialThe DCGI has approved the company's remdesivir 100 mg per vial for restricted emergency use in India as part of the regulator's accelerated...
- Solara Active Pharma to conduct internal probe on Nizatidine API amid Mylan recall"We understand from Mylan NV's press release dated January 8, 2020, that Mylan Pharmaceuticals has initiated a voluntary recall of three lo...
- Biocon-Mylan's cancer drug gets USFDA nodFulphila is expected to contribute to Biocon’s revenue in FY19, as well as to its profits through a profitshare arrangement with Mylan.
- USFDA okays Mylan, Biocon's biosimilar of cancer drug HerceptinOgivri is the first USFDA approved biosimilar to Herceptin and the first biosimilar from Mylan and Biocon's joint portfolio approved in the...
- USFDA accepts Mylan's BLA for proposed biosimilar PegfilgrastimThe proposed biosimilar Pegfilgrastim is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace, the ...
- Mylan fails in $26 bn bid to buy fellow drugmaker PerrigoMylan NV's $26 bn hostile bid for Perrigo collapsed on Friday after the Netherlands-based drugmaker failed to secure at least half of Perri...
- FIPB clears Mylan's Rs 4,960-crore FDI proposalForeign Investment Promotion Board (FIPB) cleared FDI proposal of Mylan Laboratories entailing a capital inflow of Rs 4,960 crore.
- Mylan launches hepatitis-C Sovaldi tablets in IndiaSovaldi is sold by Mylan's dedicated sales force as part of its Hepato Care segment.
- Mylan Pharmaceuticals launches generic hepatitis C drug MyHep in IndiaUS-based company's Indian arm Mylan NV has launched generic Sofosbuvir tablets in strength of 400 mg under the name MyHep in the country, i...
- Teva offers to buy Mylan for $40.1 billionTeva, the world’s biggest maker of generic medicines, offered $82 a share in cash and stock for Mylan, according to a statement.
- US drugmaker Mylan to acquire Famy Care for $750 MillionMylan will pay $750 million to buy the women’s health business of Mumbai-based Famy Care and expand its presence in the market for women’s ...
- Mylan may buy contraceptive co Famy Care for Rs 3,000 croreMylan is said to have pipped private equity bids from Bain Capital and Advent to move closer to a deal. Hong Kong-based AIF Capital holds 1...
- Mylan-Abbott deal gets CCI green signalThe CCI observed that "there is horizontal overlap" between the pharmaceutical products of Mylan and Abbott in India with respect to certai...
- Mylan launches breast cancer drug in IndiaDrug major Mylan Inc today said it has launched breast cancer drug Hertraz Herceptin in India.
- Strides Arcolab surges over 7 pc as FIPB clears Mylan's FDI proposalSince Mylan's investment proposal is of over Rs 1,200 crore, it will go to the Cabinet Committee on Economic Affairs for final approval.
- CCI gives green signal to Mylan-Unichem dealIt observed that the proposed acquisition by Mylan was with the intent to export products to be manufactured at the said facility.
- Biocon Inks Pact with Mylan for generic insulinIn 2009, Mylan and Biocon had come together to develop five blockbuster biologic drugs in cancer and pain areas.
- Ranbaxy rebounds a day after Mylan sues FDA to block Lipitor copyMylan Pharma has sued the US FDA, seeking to terminate Ranbaxy's exclusive marketing rights to sell a lowcost version of Lipitor for six mo...
- Mylan sues FDA to block Ranbaxy’s Lipitor copyMylan Pharmaceuticals has sued the US drug regulator, seeking to terminate Ranbaxy Laboratories’ exclusive marketing rights to sell a lowco...
Load More
